Free Trial

Aadi Bioscience Q4 2022 Earnings Report

Aadi Bioscience logo
$2.98 -0.15 (-4.79%)
As of 01/17/2025 04:00 PM Eastern

Aadi Bioscience EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Aadi Bioscience Revenue Results

Actual Revenue
$5.23 million
Expected Revenue
$4.58 million
Beat/Miss
Beat by +$650.00 thousand
YoY Revenue Growth
N/A

Aadi Bioscience Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Aadi Bioscience Earnings Headlines

Aadi Bioscience Leads 3 Promising US Penny Stocks
Aadi Bioscience’s Strategic Agreements and Funding Moves
Outperform BTC without owning any crypto?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
Aadi Bioscience rockets 72% on key updates
See More Aadi Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email.

About Aadi Bioscience

Aadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Aadi Bioscience Profile

More Earnings Resources from MarketBeat